FormsNet3 - Blank Form


 

 
Sequence Number:    

 

 
Date Received: __ __ __ __ - __ __- __ __  

 

 
CIBMTR Center Number:    

 

 
CIBMTR Recipient ID:    

 

 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

HCT Type: (check all that apply) 

 

 
Autologous

 

 
Allogeneic, unrelated

 

 
Allogeneic, related

Product type: (check all that apply) 

 

 
Bone marrow

 

 
PBSC

 

 
Single cord blood unit

 

 
Multiple cord blood units

 

 
Other product

 

 
Specify:    

 

 
Is this the report of a second or subsequent transplant for the same disease?

  
 

yes  
 

no  

 

 
1  Is this recipient a registered participant in the United States Immunodeficiency Network (USIDNET)?

    
 

yes  
 

no  

 

 
2  USIDNET ID:    

 

 
3  What is the diagnosis?

    
 

Chediak-Higashi syndrome  

 
Griscelli syndrome type 2  

 
Hermansky-Pudlak syndrome type 2  

 
Other pigmentary dilution disorder  

 

 
4  Specify other PDD diagnosis:    

 

 
5  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

 

 
6  Was genetic testing used to confirm the diagnosis?

    
 

yes  
 

no  
 

Unknown  

 

 
7  Was documentation submitted to the CIBMTR?

    
 

yes  
 

no  

  Key Fields 

Subsequent Transplant 

  Disease Assessment at Diagnosis Questions: 1 - 7

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 1 / 12



 

 
8  Cytotoxic T-cell activity

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
9  Date sample collected

    
 

Known  
 

Unknown  

 

 
10  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
11  Degranulation of cytolytic lymphocytes (CD107a expression)

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
12  Date sample collected

    
 

Known  
 

Unknown  

 

 
13  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
14  Granulocyte chemotaxis

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
15  Date sample collected

    
 

Known  
 

Unknown  

 

 
16  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
17  Natural killer cell activity

    (against K562 cells)  

 
Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
18  Date sample collected

    
 

Known  
 

Unknown  

 

 
19  Date sample collected: __ __ __ __ - __ __- __ __  

  Assessment of Immunologic Function at Diagnosis Questions: 8 - 35

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 2 / 12



 

 
20  Phytohemagglutinin (PHA)

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
21  Date sample collected

    
 

Known  
 

Unknown  

 

 
22  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
23  Platelet aggregation

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
24  Date sample collected

    
 

Known  
 

Unknown  

 

 
25  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
26  Did the recipient receive supplemental intravenous immunoglobulins (IVIG)?

    
 

yes  
 

no  

 

 
27  Was therapy ongoing within three months of immunoglobulin testing?

    
 

yes  
 

no  

Specify the quantitative immunoglobulins measured at diagnosis: 

 

 
28  IgG

    
 

Known  
 

Unknown  

 

 
29     

 

 

 
mg/dL  

 
g/dL  

 
g/L  

 

 
30  IgM

    
 

Known  
 

Unknown  

 

 
31     

 

 

 
mg/dL  

 
g/dL  

 
g/L  

 

 
32  IgA

    
 

Known  
 

Unknown  

 

 
33     

 

 

 
mg/dL  

 
g/dL  

 
g/L  

 

 
34  IgE

    
 

Known  
 

Unknown  

 

 
35     IU/mL 

  Lymphocyte Analysis at Diagnosis Questions: 36 - 51

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 3 / 12



 

 
36  Were lymphocyte analyses performed?

    
 

yes  
 

no  

Specify the following lymphocyte analyses performed at diagnosis: 

 

 
37  Date sample collected: __ __ __ __ - __ __- __ __  

Specify the following lymphocyte analyses performed at diagnosis: 

 

 
38  CD3 (T cells)

    
 

Known  
 

Unknown  

 

 
39     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
40  CD4 (T helper cells)

    
 

Known  
 

Unknown  

 

 
41     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
42  CD8 (cytotoxic T cells)

    
 

Known  
 

Unknown  

 

 
43     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
44  CD20 (B lymphocyte cells)

    
 

Known  
 

Unknown  

 

 
45     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
46  CD56 (natural killer (NK) cells)

    
 

Known  
 

Unknown  

 

 
47     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
48  CD4+ / CD45RA+ (naive T cells)

    
 

Known  
 

Unknown  

 

 
49     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
50  CD4+ / CD45RO+ (memory T cells)

    
 

Known  
 

Unknown  

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 4 / 12



 

 
51     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

Indicate which of the following manifestations of the disease were present between diagnosis and the start of the preparative regimen: 

 

 
52  Giant leukocyte granules

    
 

yes  
 

no  
 

Unknown  

 

 
53  Neutropenia (ANC < 1.0 x 109 /L)

    
 

yes  
 

no  
 

Unknown  

 

 
54  Thrombocytopenia (platelets < 100 x 109 /L)

    
 

yes  
 

no  
 

Unknown  

 

 
55  Facial dysmorphisms

    (any of the following: epicanthal folds, broad nasal root, posteriorly rotated ears, retrognathia) 

 
yes  

 
no  

 
Unknown  

 

 
56  Fair hair and/or abnormal accumulation of pigment at microscopic examination of hair

    
 

yes  
 

no  
 

Unknown  

 

 
57  Ocular albinism

    
 

yes  
 

no  
 

Unknown  

 

 
58  Skin albinism / fair skin

    
 

yes  
 

no  
 

Unknown  

 

 
59  Bleeding diathesis

    
 

yes  
 

no  
 

Unknown  

 

 
60  Bleeding from the GI tract

    
 

yes  
 

no  

 

 
61  Easy bruising

    
 

yes  
 

no  

 

 
62  Hematuria

    
 

yes  
 

no  

 

 
63  Oral bleeding

    
 

yes  
 

no  

 

 
64  Recurrent nosebleeds

    
 

yes  
 

no  

 

 
65  Other bleeding

    
 

yes  
 

no  

 

 
66  Specify other bleeding:    

  Disease Involvement Between Diagnosis and the Start of the Preparative Regimen(Conditioning) Questions: 52 - 78

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 5 / 12



 

 
67  Were there any clinical neurologic abnormalities present?

    
 

yes  
 

no  
 

Unknown  

Specify neurologic abnormality or abnormalities: 

 

 
68  Abnormal gait

    
 

yes  
 

no  

 

 
69  Areflexia

    
 

yes  
 

no  

 

 
70  Ataxia and/or other symptoms of cerebellar dysfunction

    
 

yes  
 

no  

 

 
71  Developmental delay

    
 

yes  
 

no  

 

 
72  Was the recipient’s IQ tested?

    
 

yes  
 

no  

 

 
73  Date IQ was tested: __ __ __ __ - __ __- __ __  

 

 
74  IQ test instrument

    
 

Kaufman Assessment Battery for Children  

 
Raven’s Progressive Matrices  

 
Stanford-Binet  

 
Wechsler Adult Intelligence Scale  

 
Wechsler Intelligence Scale for Children  

 
Woodcock-Johnson Tests of Cognitive Abilities  

 

 
75  IQ score:    

 

 
76  Seizures

    
 

yes  
 

no  

 

 
77  Other neurologic abnormality

    
 

yes  
 

no  

 

 
78  Specify other neurologic abnormality:    

 

 
79  Did the recipient develop features of an accelerated phase?

    
 

yes  
 

no  
 

Unknown  

 

 
80  Number of accelerated phases recorded:    

 

 
81  Date first accelerated phase detected

    
 

Known  
 

Unknown  

 

 
82  Date first accelerated phase was detected: __ __ __ __ - __ __- __ __  

  Accelerated Phase(AP) Between Diagnosis and the Start of the Preparative Regimen(Conditioning) Questions: 79 - 105

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 6 / 12



 

 
83  Abnormal CSF

    (WBC > 5 cells/µL, elevated protein)  

 
yes  

 
no  

 
Unknown  

 

 
84  Abnormal liver function

    
 

yes  
 

no  
 

Unknown  

 

 
85  Anemia

    (Hgb<10 g/dL)  

 
yes  

 
no  

 
Unknown  

 

 
86  Cytomegalovirus (CMV)

    (associated with accelerated phase)  

 
yes  

 
no  

 
Unknown  

 

 
87  Epstein-Barr virus (EBV)

    (associated with accelerated phase)  

 
yes  

 
no  

 
Unknown  

 

 
88  Other viral infection associated with accelerated phase

    (not CMV or EBV)  

 
yes  

 
no  

 
Unknown  

 

 
89  Specify other infection:    

 

 
90  Dense bodies (delta granules) on electron micrograph (EM) of platelets

    
 

yes  
 

no  
 

Unknown  

 

 
91  Elevated triglycerides

    
 

yes  
 

no  
 

Unknown  

 

 
92  Fevers

    (>38.5° C or > 101.3°  F for >7 days)  

 
yes  

 
no  

 
Unknown  

 

 
93  Hemophagocytosis

    
 

yes  
 

no  
 

Unknown  

 

 
94  Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

    
 

yes  
 

no  
 

Unknown  

 

 
95  Hyperferritinemia

    (serum ferritin > 500 ng/mL or 500 µg/dL)  

 
yes  

 
no  

 
Unknown  

 

 
96  Hypofibrinogenemia

    (serum fibrogen <150 mg/dL or <1.5 g/L or <4.4 µmol/L) 

 
yes  

 
no  

 
Unknown  

 

 
97  Hyponatremia

    (serum sodium <135 mg/dL)  

 
yes  

 
no  

 
Unknown  

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 7 / 12



 

 
98  Lymphadenopathy

    
 

yes  
 

no  
 

Unknown  

 

 
99  CSF lymphocytosis

    
 

yes  
 

no  
 

Unknown  

 

 
100  Neurologic dysfunction

    (e.g. seizures, meningitis signs)  

 
yes  

 
no  

 
Unknown  

 

 
101  Neutropenia (ANC < 1.0 x 109 /L)

    
 

yes  
 

no  
 

Unknown  

 

 
102  Splenomegaly (spleen palpable > 3 cm below left costal margin)

    
 

yes  
 

no  
 

Unknown  

 

 
103  Thrombocytopenia (platelets < 100 x 109 /L)

    
 

yes  
 

no  
 

Unknown  

 

 
104  Other feature associated with accelerated phase

    
 

yes  
 

no  
 

Unknown  

 

 
105  Specify other feature:    

 

 
106  Was therapy given?

    
 

yes  
 

no  

Specify therapy given: 

 

 
107  Acyclovir

    
 

yes  
 

no  

 

 
108  Alemtuzumab (Campath)

    
 

yes  
 

no  

 

 
109  Antithymocyte globulin (ATG)

    
 

yes  
 

no  

 

 
110  Corticosteroids

    
 

yes  
 

no  

 

 
111  Cyclosporine (CSA, Neoral, Sandimmune)

    
 

yes  
 

no  

 

 
112  Etoposide (VP-16, VePesid)

    
 

yes  
 

no  

 

 
113  Ganciclovir (DHPG)

    
 

yes  
 

no  

  Pre-HCT Therapy Questions: 106 - 119

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 8 / 12



 

 
114  Intrathecal methotrexate (IT MTX)

    
 

yes  
 

no  

 

 
115  Intravenous immune globulin (IVIG)

    
 

yes  
 

no  

 

 
116  Interferon-α (Intron, Roferon) (includes PEG)

    
 

yes  
 

no  

 

 
117  Rituximab (Rituxan, MabThera)

    
 

yes  
 

no  

 

 
118  Other therapy

    
 

yes  
 

no  

 

 
119  Specify other therapy:    

 

 
120  Cytotoxic T-cell activity

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
121  Date sample collected

    
 

Known  
 

Unknown  

 

 
122  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
123  Degranulation of cytolytic lymphocytes (CD107a expression)

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
124  Date sample collected

    
 

Known  
 

Unknown  

 

 
125  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
126  Granulocyte chemotaxis

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
127  Date sample collected

    
 

Known  
 

Unknown  

  Assessment of Immunologic Function at Last Evaluation Prior to the Start of Preparative Regimen Questions: 120 - 147

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 9 / 12



 

 
128  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
129  Natural killer cell activity

    (against K562 cells)  

 
Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
130  Date sample collected

    
 

Known  
 

Unknown  

 

 
131  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
132  Phytohemagglutinin (PHA)

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
133  Date sample collected

    
 

Known  
 

Unknown  

 

 
134  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
135  Platelet aggregation

    
 

Absent  (<10% of control) 

 
Low  (10-30% of control) 

 
Normal  (>30% of control) 

 
Not done  

 

 
136  Date sample collected

    
 

Known  
 

Unknown  

 

 
137  Date sample collected: __ __ __ __ - __ __- __ __  

Specify the quantitative immunoglobulins last measured prior to the preparative regimen: 

 

 
138  Did the recipient receive supplemental intravenous immunoglobulins (IVIG)?

    
 

yes  
 

no  

 

 
139  Was therapy ongoing within three months of immunoglobulin testing?

    
 

yes  
 

no  

 

 
140  IgG

    
 

Known  
 

Unknown  

 

 
141     

 

 

 
mg/dL  

 
g/dL  

 
g/L  

 

 
142  IgM

    
 

Known  
 

Unknown  

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 10 / 12



 

 
143     

 

 

 
mg/dL  

 
g/dL  

 
g/L  

 

 
144  IgA

    
 

Known  
 

Unknown  

 

 
145     

 

 

 
mg/dL  

 
g/dL  

 
g/L  

 

 
146  IgE

    
 

Known  
 

Unknown  

 

 
147     IU/mL 

 

 
148  Were lymphocyte analyses performed?

    
 

yes  
 

no  

 

 
149  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
150  CD3 (T cells)

    
 

Known  
 

Unknown  

 

 
151     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
152  CD4 (T helper cells)

    
 

Known  
 

Unknown  

 

 
153     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
154  CD8 (cytotoxic T cells)

    
 

Known  
 

Unknown  

 

 
155     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
156  CD20 (B lymphocyte cells)

    
 

Known  
 

Unknown  

 

 
157     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
158  CD56 (natural killer (NK) cells)

    
 

Known  
 

Unknown  

 

 
159     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

  Lymphocyte Analysis at Last Evaluation Prior to the Start of the Preparative Regimen (Conditioning) Questions: 148 - 163

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 11 / 12



 

 
160  CD4+ / CD45RA+ (naive T cells)

    
 

Known  
 

Unknown  

 

 
161     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
162  CD4+ / CD45RO+ (memory T cells)

    
 

Known  
 

Unknown  

 

 
163     

 

 

 
x 109/L (x 103/mm3)  

 
x 106/L  

 

 
164  What was the disease status?

    
 

No prior accelerated phase  

 
In remission from accelerated phase  

 
In accelerated phase  

 
Unknown  

 

 
165  Date assessed: __ __ __ __ - __ __- __ __  

 

 
First Name:    

 

 
Last Name:    

 

 
E-mail address:    

 

 
Date: __ __ __ __ - __ __- __ __  

  Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen(Conditioning) Questions: 164 - 165

Form 2056 R1.0: Pigmentary Dilution Disorder (PDD) Pre-HCT Data  
Center:  CRID: 

             CIBMTR Form 2056 revision 1.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 12 / 12